Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases

Rolandsson Enes, Sara LU orcid ; Krasnodembskaya, Anna D. ; English, Karen ; Dos Santos, Claudia C. and Weiss, Daniel J. (2021) In Frontiers in Pharmacology 12.
Abstract

Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.

Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cell therapy, lung diseases, mesenchymal stromal cells (MSCs), mscs, respiratory diseases and disorders
in
Frontiers in Pharmacology
volume
12
article number
647652
publisher
Frontiers Media S. A.
external identifiers
  • pmid:33953680
  • scopus:85105171612
ISSN
1663-9812
DOI
10.3389/fphar.2021.647652
language
English
LU publication?
yes
id
7f739f53-94c4-49c4-ad90-abb8878b1deb
date added to LUP
2021-05-21 15:59:29
date last changed
2024-04-20 06:23:05
@article{7f739f53-94c4-49c4-ad90-abb8878b1deb,
  abstract     = {{<p>Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.</p>}},
  author       = {{Rolandsson Enes, Sara and Krasnodembskaya, Anna D. and English, Karen and Dos Santos, Claudia C. and Weiss, Daniel J.}},
  issn         = {{1663-9812}},
  keywords     = {{cell therapy; lung diseases; mesenchymal stromal cells (MSCs); mscs; respiratory diseases and disorders}},
  language     = {{eng}},
  month        = {{04}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Pharmacology}},
  title        = {{Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases}},
  url          = {{http://dx.doi.org/10.3389/fphar.2021.647652}},
  doi          = {{10.3389/fphar.2021.647652}},
  volume       = {{12}},
  year         = {{2021}},
}